Larry Miller founded Apnimed in 2017 with Drs. Andrew Wellman and Luigi Taranto and serves as CEO and Board Chair. Previously, he was co-founder, CEO, and board member at Macrolide Pharmaceuticals, a company developing novel antibiotics. Since 1991, he has founded or co-founded nine additional life sciences/healthcare companies including HPR, Avicenna, PharMetrics, ImpactRx, Serenex, Optio Research, Tetraphase and Activate Networks, and has served as senior manager, CEO, or board member in each case. Two of these companies completed public offerings and seven were acquired.
He also co-founded the Mediphase funds, where he led investments in both private and public life sciences/healthcare companies, having served previously in a similar role at Hambrecht & Quist Capital Management. Dr. Miller received an AB from Harvard College, an MD from Harvard Medical School, and completed clinical training in internal medicine and pulmonary disease at the Massachusetts General Hospital. He is board-certified in Internal Medicine, Pulmonary Disease, and Clinical Pharmacology.
We must think beyond one-size-fits-all solutions and embrace the diversity of obstructive sleep apnea. This means continuing to innovate, collaborating across sectors, and keeping patients at the center of every decision.